---
title: "Lunai Bioworks discovers 3 Parkinson's subtypes, targets for $13B market. Exciting progress in precision therapeutics."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269090661.md"
description: "Today, in Sacramento, California, Lunai Bioworks (NASDAQ: LNAI), a biotechnology company utilizing AI to develop precision therapeutics, revealed the discovery of three significant subtypes of Parkinson's disease. They have also prioritized drug targets that show promise for treatment."
datetime: "2025-12-09T12:46:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269090661.md)
  - [en](https://longbridge.com/en/news/269090661.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269090661.md)
generator: "portal-rs"
---

# Lunai Bioworks discovers 3 Parkinson's subtypes, targets for $13B market. Exciting progress in precision therapeutics.

Today, in Sacramento, California, Lunai Bioworks (NASDAQ: LNAI), a biotechnology company utilizing AI to develop precision therapeutics, revealed the discovery of three significant subtypes of Parkinson's disease. They have also prioritized drug targets that show promise for treatment.

### Related Stocks

- [RENB.US](https://longbridge.com/en/quote/RENB.US.md)
- [LNAI.US](https://longbridge.com/en/quote/LNAI.US.md)

## Related News & Research

- [Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit | LNAI Stock News](https://longbridge.com/en/news/297195535.md)
- [Lunai Bioworks announces availability of CEO shareholder letter](https://longbridge.com/en/news/290058803.md)
- [Lunai Bioworks postpones special meeting to May 8 to allow broker discretionary voting](https://longbridge.com/en/news/284453488.md)
- [09:30 ETLanai Launches AI @ Work Operating System to Help Enterprises Close the AI Accountability Gap](https://longbridge.com/en/news/283010611.md)
- [12:16 ETLunakai Highlights Public Health and Stress Awareness in April](https://longbridge.com/en/news/281400535.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**